204 related articles for article (PubMed ID: 28118719)
1. [Breast Cancer - Specifics of Gynecological Care and Counseling].
Weinberger V; Zikán M
Klin Onkol; 2016; 29 Suppl 3():S7-15. PubMed ID: 28118719
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Krásenská M
Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723
[TBL] [Abstract][Full Text] [Related]
3. [Pregnancy after Treatment of Breast Cancer].
Petráková K; Holánek M
Klin Onkol; 2016; 29 Suppl 3():S23-28. PubMed ID: 28118721
[TBL] [Abstract][Full Text] [Related]
4. [Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
Petráková K; Krásenská M; Valík D; Holánek M; Palácová M; Demlová R
Klin Onkol; 2016; 29 Suppl 3():S50-57. PubMed ID: 28118724
[TBL] [Abstract][Full Text] [Related]
5. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
6. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
8. The role of tamoxifen in the treatment and prevention of breast cancer.
Jordan VC
Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
[TBL] [Abstract][Full Text] [Related]
9. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects].
Palácová M
Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
[TBL] [Abstract][Full Text] [Related]
11. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
12. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
13. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
14. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
15. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
16. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
17. Fertility preservation options in breast cancer patients.
Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
